Preferences and Perspectives of Specialist Multiple Sclerosis Nurses and Patients with Multiple Sclerosis Regarding the New RebiSmart^® 3.0 Autoinjector versus Other Assistive Devices

References

• Filippi M, Bar-Or A, Piehl F, et al. Multiple sclerosis. Nat Rev Dis Primers. 2018;4(1):43. doi:10.1038/s41572-018-0041-4
   PubMed Web of Science ®Google Scholar
• Hanson KA, Agashivala N, Wyrwich KW, Raimundo K, Kim E, Brandes DW. Treatment selection and experience in multiple sclerosis: survey of neurologists. Patient Prefer Adherence. 2014;8:415–422. doi:10.2147/ppa.S53140
   PubMed Web of Science ®Google Scholar
• Gromisch ES, Turner AP, Leipertz SL, Beauvais J, Haselkorn JK. Risk factors for suboptimal medication adherence in persons with multiple sclerosis: development of an electronic health record-based explanatory model for disease-modifying therapy use. Arch Phys Med Rehabil. 2020;101(5):807–814. doi:10.1016/j.apmr.2019.11.005
   PubMed Web of Science ®Google Scholar
• Pozzilli C, Schweikert B, Ecari U, Oentrich W. BetaPlus Study group. Supportive strategies to improve adherence to IFN beta-1b in multiple sclerosis--results of the betaPlus observational cohort study. J Neurol Sci. 2011;307(1–2):120–126. doi:10.1016/j.jns.2011.04.026
   PubMed Web of Science ®Google Scholar
• Bayas A. Improving adherence to injectable disease-modifying drugs in multiple sclerosis. Expert Opin Drug Deliv. 2013;10(3):285–287. doi:10.1517/17425247.2013.763793
   PubMed Web of Science ®Google Scholar
• Rieckmann P, Ziemssen T, Penner IK, et al. Adherence to subcutaneous interferon beta-1a in multiple sclerosis patients receiving periodic feedback on drug use by discussion of readouts of their rebismart((R)) injector: results of the prospective cohort study REBIFLECT. Adv Ther. 2022;39(6):2749–2760. doi:10.1007/s12325-022-02100-w
   PubMed Web of Science ®Google Scholar
• US FDA. BETACONNECT™ autoinjector. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/103471s5201lbl.pdf. Accessed February 09, 2024.
   Google Scholar
• Hoffmann FA, Trenova A, Llaneza MA, et al. Patient satisfaction with ExtaviPro 30G, a new auto-injector for administering interferon beta-1b in multiple sclerosis: results from a real-world, observational EXCHANGE study. BMC Neurol. 2017;17(1):156. doi:10.1186/s12883-017-0928-9
   PubMedGoogle Scholar
• US FDA. AVONEX (interferon beta-1a) injection, for intramuscular injection Initial U.S. Approval; 1996. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103628s5189lbl.pdf. Accessed February 09, 2024.
   Google Scholar
• US FDA. PLEGRIDY (peginterferon beta-1a) injection, for subcutaneous injection Initial U.S. Approval; 2014. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125499lbl.pdf. Accessed February 09, 2024.
   Google Scholar
• Devonshire VA, Verdun Di Cantogno E. Review of subcutaneous interferon beta-1a, delivered via the electronic self-injection device RebiSmart, for the treatment of multiple sclerosis. Ther Deliv. 2011;2(11):1455–1465. doi:10.4155/tde.11.116
   PubMedGoogle Scholar
• Lugaresi A. RebiSmart (version 1.5) device for multiple sclerosis treatment delivery and adherence. Expert Opin Drug Deliv. 2013;10(2):273–283. doi:10.1517/17425247.2013.746311
   PubMed Web of Science ®Google Scholar
• Ebers GC; PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352(9139):1498–1504. doi:10.1016/S0140-6736(98)03334-0
   PubMed Web of Science ®Google Scholar
• Prisms Study Group the University of British Columbia, MS/MRI. Analysis Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology. 2001;56(12):1628–1636. doi:10.1212/wnl.56.12.1628
   PubMed Web of Science ®Google Scholar
• Filipi M, Jack S. Interferons in the treatment of multiple sclerosis: a clinical efficacy, safety, and tolerability update. Int J MS Care. 2020;22(4):165–172. doi:10.7224/1537-2073.2018-063
   PubMedGoogle Scholar
• EMA. Rebif 22 micrograms solution for injection in pre-filled syringe SmPC; 2023.
   Google Scholar
• Lugaresi A, De Robertis F, Clerico M, et al. Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon beta-1a using an electronic device: the RIVER study. Expert Opin Drug Deliv. 2016;13(7):931–935. doi:10.1517/17425247.2016.1148029
   PubMed Web of Science ®Google Scholar
• Lugaresi A, Florio C, Brescia-Morra V, et al. Patient adherence to and tolerability of self-administered interferon beta-1a using an electronic autoinjection device: a multicentre, open-label, Phase IV study. BMC Neurol. 2012;12:7. doi:10.1186/1471-2377-12-7
   PubMed Web of Science ®Google Scholar
• Arnaud L. Evolution of the RebiSmart® autoinjector device in support of adherence to subcutaneous interferon beta-1a therapy for relapsing multiple sclerosis. Amsterdam, The Netherlands: ECTRIMS; 2022. Available from: https://www.merckneurology.com/content/dam/web/healthcare/biopharma/neurology/merckneurology/newDesign/congress/documents/ECTRIMS/Posters/ECTRIMS_Poster_blue_2_2022.pdf. Accessed February 09, 2024.
   Google Scholar
• Lin Y. Evolution of the rebismart®autoinjector device to improve usability in support of adherence to subcutaneous interferon beta-1a therapy for relapsing multiple sclerosis. Cairo, Egypt: MENACTRIMS; 2022. Available from: https://www.sciencedirect.com/science/article/pii/S2211034822008653. Accessed February 09, 2024.
   Google Scholar
• Burke T, Dishon S, McEwan L, Smrtka J. The evolving role of the multiple sclerosis nurse: an international perspective. Int J MS Care. 2011;13(3):105–112. doi:10.7224/1537-2073-13.3.105
   PubMedGoogle Scholar
• Calfee JE. A representative survey of MS patients on attitudes toward the benefits and risks of drug therapy; 2006.
   Google Scholar
• Qualtrics. Getting started with maxdiff projects; 2023, Available from: https://www.qualtrics.com/support/conjoint-project/getting-started-conjoints/getting-started-maxdiff/getting-started-with-maxdiff-projects/. Accessed February 09, 2024.
   Google Scholar
• Survey Analytics: maximum difference analysis; 2024. Available from: https://www.surveyanalytics.com/maximum-difference-analysis.html. Accessed February 09, 2024.
   Google Scholar
• QuestionPro. Anchored maximum difference analysis; 2023, Available from: https://www.questionpro.com/help/anchored-maxdiff.html. Accessed February 09, 2024.
   Google Scholar
• Devonshire VA, Feinstein A, Moriarty P. Adherence to interferon beta-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study. BMC Res Notes. 2016;9:148. doi:10.1186/s13104-016-1948-z
   PubMedGoogle Scholar
• Krol M, de Voer G, Osowski U. Patient adherence to subcutaneous IFN beta-1a injections using the RebiSmart® injection device: a retrospective real-world study among Dutch and German patients with multiple sclerosis. Patient Prefer Adherence. 2017;11:1189–1196. doi:10.2147/PPA.S130985
   PubMed Web of Science ®Google Scholar
• Valis M, Sarlakova J, Haluskova S, et al. An observational study demonstrating the adherence and ease of use of the injector device, RebiSmart®. Expert Opin Drug Deliv. 2020;17(5):719–724. doi:10.1080/17425247.2020.1742694
   PubMed Web of Science ®Google Scholar
• Lugaresi A, Rottoli MR, Patti F. Fostering adherence to injectable disease-modifying therapies in multiple sclerosis. Expert Rev Neurother. 2014;14(9):1029–1042. doi:10.1586/14737175.2014.945523
   PubMed Web of Science ®Google Scholar
• Bittner B, Schmit Chiesi C, Kharawala S, Kaur G, Schmidt J. Connected drug delivery devices to complement drug treatments: potential to facilitate disease management in home setting. Med Devices. 2019;12:101–127. doi:10.2147/MDER.S198943
   Web of Science ®Google Scholar
• Coyne M, Rinaldi A, Brigham K, et al. Impact of routines and rituals on burden of treatment, patient training, cognitive load, and anxiety in self-injected biologic therapy. Patient Prefer Adherence. 2022;16:2593–2607. doi:10.2147/PPA.S375037
   PubMed Web of Science ®Google Scholar
• EPHMRA. Code of conduct; 2022. Available from: https://www.ephmra.org/sites/default/files/2022-08/EPHMRA%202022%20Code%20of%20Conduct.pdf. Accessed February 09, 2024.
   Google Scholar